How to buy Ambrx Biopharma stock (Ambrx Biopharma)

Ambrx Biopharma is a biotechnology business based in the US. Ambrx Biopharma shares (AMAM) are listed on the NASDAQ and all prices are listed in US Dollars. Ambrx Biopharma employs 87 staff and has a trailing 12-month revenue of around $4.1 million.

Our top picks for where to buy Ambrx Biopharma IncAmerican Depositary Shares stock

Buy Ambrx Biopharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Ambrx Biopharma stock price (NASDAQ: AMAM)

Use our graph to track the performance of AMAM stocks over time.

Ambrx Biopharma shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$12.69 - $28.15
50-day moving average more info button	$25.85
200-day moving average more info button	$18.23
Wall St. target price	$28.67
PE ratio more info button	66.6667
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.42

Is it a good time to buy Ambrx Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Ambrx Biopharma stock undervalued or overvalued?

Valuing Ambrx Biopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ambrx Biopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ambrx Biopharma's P/E ratio

Ambrx Biopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 67x. In other words, Ambrx Biopharma shares trade at around 67x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Ambrx Biopharma's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

• Acceleron Pharma (XLRN.US): 0.00
• Global Blood Therapeutics (GBT.US): 0.00
• Theravance Biopharma (TBPH.US): 0.00

Ambrx Biopharma financials

Revenue TTM	$4.1 million
Gross profit TTM	$7.4 million
Return on assets TTM	-18.62%
Return on equity TTM	-37.23%
Profit margin	0%
Book value	$3.85
Market Capitalization more info button	$1.8 billion

TTM: trailing 12 months

Ambrx Biopharma share dividends

We're not expecting Ambrx Biopharma to pay a dividend over the next 12 months.

You may also wish to consider:

Have Ambrx Biopharma's shares ever split?

Ambrx Biopharma's shares were split on 11 October 2023 .

Ambrx Biopharma share price volatility

Over the last 12 months, Ambrx Biopharma's shares have ranged in value from as little as $12.69 up to $28.15. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ambrx Biopharma's is -2.364. This would suggest that Ambrx Biopharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Ambrx Biopharma has bucked the trend.

To put Ambrx Biopharma's beta into context you can compare it against those of similar companies.

• Acceleron Pharma (XLRN.US): 0.1314
• Global Blood Therapeutics (GBT.US): 0.4634
• Theravance Biopharma (TBPH.US): 0.251

Ambrx Biopharma overview

Ambrx Biopharma Inc. , a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California. As of March 7, 2024, Ambrx Biopharma Inc. operates as a subsidiary of Johnson & Johnson.

Frequently asked questions

null
What percentage of Ambrx Biopharma is owned by insiders or institutions?
Currently 2.095% of Ambrx Biopharma shares are held by insiders and 103.43% by institutions. How many people work for Ambrx Biopharma?
Latest data suggests 87 work at Ambrx Biopharma. When does the fiscal year end for Ambrx Biopharma?
Ambrx Biopharma's fiscal year ends in December. Where is Ambrx Biopharma based?
Ambrx Biopharma's address is: 10975 North Torrey Pines Road, La Jolla, CA, United States, 92037 What is Ambrx Biopharma's ISIN number?
Ambrx Biopharma's international securities identification number is: US02290A1025